SEC Form 4 · accession 0001209191-17-026602
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marion McCourt
Officer — Principal Operating Officer
Period of report
Apr 7, 2017
Accepted (ET)
Apr 11, 2017 · 5:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $15.13 | Apr 7, 2017 | A | 465,000 | A | — | Apr 7, 2027 | Common Shares | 465,000 | 465,000 | D |
Explanation of responses
- F125% of the common shares underlying the option vest and become exercisable on April 7, 2018; the balance of the common shares vest in a series of 12 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Vesting is subject to acceleration in specified circumstances, including a change in control of the Issuer or the Reporting Person's termination without cause or resignation for good reason.